Stock Events

Stock Events

Biotron 

$0.001500
8
+$0.00+15.38%Wednesday 13:40

Statistics

Day High
0.0015
Day Low
0.0015
52W High
0.10144
52W Low
0.0011
Volume
400,000
Avg. Volume
10,319
Mkt Cap
4.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Aug 23Expected
Q2 2021
Q4 2021
Q2 2022
Q4 2022
Q2 2023
Q4 2023
Q2 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-1.03MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is a leading biopharmaceutical company that competes with Biotron in the development of antiviral drugs, including treatments for HIV and hepatitis, areas where Biotron also focuses its research efforts.
Arbutus Biopharma
ABUS
Mkt Cap881.57M
Arbutus Biopharma Corporation is involved in the discovery and development of therapies for hepatitis B, directly competing with Biotron's efforts in antiviral research.
Moderna
MRNA
Mkt Cap75.86B
Moderna, Inc. is known for its mRNA technology platform, which has potential applications in creating vaccines and therapies for viral infections, competing with Biotron's focus on infectious diseases.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline plc is a global healthcare company that develops and markets vaccines and medications for a wide range of infectious diseases, competing with Biotron's research in similar areas.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for various infectious diseases, including HIV, directly competing with Biotron's research focus.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. is involved in the development and commercialization of vaccines and antiviral drugs, making it a competitor to Biotron in the infectious disease space.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals Incorporated focuses on creating transformative medicines for people with serious diseases, including viral infections, which puts it in competition with Biotron.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie Inc. works on developing therapies for chronic and complex conditions, including viral infections like hepatitis, competing with Biotron's research areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies but is expanding into other areas, including infectious diseases, potentially competing with Biotron.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments for serious medical conditions, including infectious diseases, making it a competitor to Biotron in the biopharmaceutical field.

About

Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.
Show More
CEO
Michelle Miller GCertAppFin
Employees
3
Country
Australia
ISIN
AU000000BIT4

Listings

AU
AU
BIT.AU
OTC Link
US
BITRF

0 Comments

Share your thoughts

FAQs

What is Biotron stock price today?▼
The current price of BITRF is $0.00 USD — it has increased by +15.38% in the past 24 hours. Watch Biotron stock price performance more closely on the chart.
What is Biotron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Biotron stocks are traded under the ticker BITRF.
Is Biotron stock price growing?▼
BITRF stock has risen by +0% compared to the previous week, the month change is a -92.99% fall, over the last year Biotron has showed a -90.65% decrease.
What is Biotron market cap?▼
Today Biotron has the market capitalization of 4.05M
What were Biotron earnings last quarter?▼
BITRF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biotron revenue for the last year?▼
Biotron revenue for the last year amounts to 0 USD.
What is Biotron net income for the last year?▼
BITRF net income for the last year is -1.03M USD.
How many employees does Biotron have?▼
As of November 2, 2026, the company has 3 employees.
In which sector is Biotron located?▼
Biotron operates in the Health & Wellness sector.
When did Biotron complete a stock split?▼
Biotron has not had any recent stock splits.
Where is Biotron headquartered?▼
Biotron is headquartered in Sydney, Australia.